Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- Dietary phytoestrogen, serum enterolactone and risk of prostate cancer: the cancer prostate Sweden study
- New Study Indicates Multiple Mechanisms Involved In The Inhibition Of The Growth Of LNCaP Prostate Cancer Cells By Plant Lignans
Research performed by the Department of Clinical Medicine at the University of Insubria in Italy has shed further light into the mechanisms involved in the inhibition of the growth of LNCaP prostate cancer cells by plant lignans; LNCaP cells lines were incubated with either enterolactone (70-100 microMols) or hydroxymatairesinol (70-100 microMols) for 48 hours, with estradiol (100 microMols) and the cytotoxic agent cycloheximide (10 microMols) used as the experimental controls, with results showing a concentration-dependent increase in the proportion of apoptotic cells for both substances -- enterolactone was about two-fold as effective as hydroxymatairesinol in this experiment but less than half that of cycloheximide and estradiol.
- New Study Indicates Multiple Mechanisms Involved In The Inhibition Of The Growth Of LNCaP Prostate Cancer Cells By Plant Lignans
Research performed by the Department of Clinical Medicine at the University of Insubria in Italy has shed further light into the mechanisms involved in the inhibition of the growth of LNCaP prostate cancer cells by plant lignans; LNCaP cells lines were incubated with either enterolactone (70-100 microMols) or hydroxymatairesinol (70-100 microMols) for 48 hours, with estradiol (100 microMols) and the cytotoxic agent cycloheximide (10 microMols) used as the experimental controls, with results showing a concentration-dependent increase in the proportion of apoptotic cells for both substances -- enterolactone was about two-fold as effective as hydroxymatairesinol in this experiment but less than half that of cycloheximide and estradiol.
- New Study Indicates Multiple Mechanisms Involved In The Inhibition Of The Growth Of LNCaP Prostate Cancer Cells By Plant Lignans
Research performed by the Department of Clinical Medicine at the University of Insubria in Italy has shed further light into the mechanisms involved in the inhibition of the growth of LNCaP prostate cancer cells by plant lignans; LNCaP cells lines were incubated with either enterolactone (70-100 microMols) or hydroxymatairesinol (70-100 microMols) for 48 hours, with estradiol (100 microMols) and the cytotoxic agent cycloheximide (10 microMols) used as the experimental controls, with results showing a concentration-dependent increase in the proportion of apoptotic cells for both substances -- enterolactone was about two-fold as effective as hydroxymatairesinol in this experiment but less than half that of cycloheximide and estradiol.
- New Study Indicates Multiple Mechanisms Involved In The Inhibition Of The Growth Of LNCaP Prostate Cancer Cells By Plant Lignans
Research performed by the Department of Clinical Medicine at the University of Insubria in Italy has shed further light into the mechanisms involved in the inhibition of the growth of LNCaP prostate cancer cells by plant lignans; LNCaP cells lines were incubated with either enterolactone (70-100 microMols) or hydroxymatairesinol (70-100 microMols) for 48 hours, with estradiol (100 microMols) and the cytotoxic agent cycloheximide (10 microMols) used as the experimental controls, with results showing a concentration-dependent increase in the proportion of apoptotic cells for both substances -- enterolactone was about two-fold as effective as hydroxymatairesinol in this experiment but less than half that of cycloheximide and estradiol.
- New Study Indicates Multiple Mechanisms Involved In The Inhibition Of The Growth Of LNCaP Prostate Cancer Cells By Plant Lignans
Research performed by the Department of Clinical Medicine at the University of Insubria in Italy has shed further light into the mechanisms involved in the inhibition of the growth of LNCaP prostate cancer cells by plant lignans; LNCaP cells lines were incubated with either enterolactone (70-100 microMols) or hydroxymatairesinol (70-100 microMols) for 48 hours, with estradiol (100 microMols) and the cytotoxic agent cycloheximide (10 microMols) used as the experimental controls, with results showing a concentration-dependent increase in the proportion of apoptotic cells for both substances -- enterolactone was about two-fold as effective as hydroxymatairesinol in this experiment but less than half that of cycloheximide and estradiol.
- New Study Indicates Multiple Mechanisms Involved In The Inhibition Of The Growth Of LNCaP Prostate Cancer Cells By Plant Lignans
Research performed by the Department of Clinical Medicine at the University of Insubria in Italy has shed further light into the mechanisms involved in the inhibition of the growth of LNCaP prostate cancer cells by plant lignans; LNCaP cells lines were incubated with either enterolactone (70-100 microMols) or hydroxymatairesinol (70-100 microMols) for 48 hours, with estradiol (100 microMols) and the cytotoxic agent cycloheximide (10 microMols) used as the experimental controls, with results showing a concentration-dependent increase in the proportion of apoptotic cells for both substances -- enterolactone was about two-fold as effective as hydroxymatairesinol in this experiment but less than half that of cycloheximide and estradiol.
- New Study Indicates Multiple Mechanisms Involved In The Inhibition Of The Growth Of LNCaP Prostate Cancer Cells By Plant Lignans
Research performed by the Department of Clinical Medicine at the University of Insubria in Italy has shed further light into the mechanisms involved in the inhibition of the growth of LNCaP prostate cancer cells by plant lignans; LNCaP cells lines were incubated with either enterolactone (70-100 microMols) or hydroxymatairesinol (70-100 microMols) for 48 hours, with estradiol (100 microMols) and the cytotoxic agent cycloheximide (10 microMols) used as the experimental controls, with results showing a concentration-dependent increase in the proportion of apoptotic cells for both substances -- enterolactone was about two-fold as effective as hydroxymatairesinol in this experiment but less than half that of cycloheximide and estradiol.
- New Study Indicates Multiple Mechanisms Involved In The Inhibition Of The Growth Of LNCaP Prostate Cancer Cells By Plant Lignans
Research performed by the Department of Clinical Medicine at the University of Insubria in Italy has shed further light into the mechanisms involved in the inhibition of the growth of LNCaP prostate cancer cells by plant lignans; LNCaP cells lines were incubated with either enterolactone (70-100 microMols) or hydroxymatairesinol (70-100 microMols) for 48 hours, with estradiol (100 microMols) and the cytotoxic agent cycloheximide (10 microMols) used as the experimental controls, with results showing a concentration-dependent increase in the proportion of apoptotic cells for both substances -- enterolactone was about two-fold as effective as hydroxymatairesinol in this experiment but less than half that of cycloheximide and estradiol.
- Broccoli, Cauliflower and Genetic Cancer
New study on a mouse model, at Rutgers shows that certain vegetables – broccoli and cauliflower, in particular – have natural ingredients including sulforaphane that may reduce the risk of developing hereditary cancers.
- Broccoli, Cauliflower and Genetic Cancer
New study on a mouse model, at Rutgers shows that certain vegetables – broccoli and cauliflower, in particular – have natural ingredients including sulforaphane that may reduce the risk of developing hereditary cancers.
- Broccoli, Cauliflower and Genetic Cancer
New study on a mouse model, at Rutgers shows that certain vegetables – broccoli and cauliflower, in particular – have natural ingredients including sulforaphane that may reduce the risk of developing hereditary cancers.
- Broccoli, Cauliflower and Genetic Cancer
New study on a mouse model, at Rutgers shows that certain vegetables – broccoli and cauliflower, in particular – have natural ingredients including sulforaphane that may reduce the risk of developing hereditary cancers.
- Broccoli, Cauliflower and Genetic Cancer
New study on a mouse model, at Rutgers shows that certain vegetables – broccoli and cauliflower, in particular – have natural ingredients including sulforaphane that may reduce the risk of developing hereditary cancers.
- Broccoli, Cauliflower and Genetic Cancer
New study on a mouse model, at Rutgers shows that certain vegetables – broccoli and cauliflower, in particular – have natural ingredients including sulforaphane that may reduce the risk of developing hereditary cancers.
- Encouraging Results for Folic Acid for Cancer Prevention
Small study in CANCER indicates finds that 31 of 43 patients with the precancerous laryngeal lesion called leucoplakia demonstrated 50 percent or greater reduction in the lesion size after six months of taking folate supplements.
- Encouraging Results for Folic Acid for Cancer Prevention
Small study in CANCER indicates finds that 31 of 43 patients with the precancerous laryngeal lesion called leucoplakia demonstrated 50 percent or greater reduction in the lesion size after six months of taking folate supplements.
- Encouraging Results for Folic Acid for Cancer Prevention
Small study in CANCER indicates finds that 31 of 43 patients with the precancerous laryngeal lesion called leucoplakia demonstrated 50 percent or greater reduction in the lesion size after six months of taking folate supplements.
- Encouraging Results for Folic Acid for Cancer Prevention
Small study in CANCER indicates finds that 31 of 43 patients with the precancerous laryngeal lesion called leucoplakia demonstrated 50 percent or greater reduction in the lesion size after six months of taking folate supplements.
- Encouraging Results for Folic Acid for Cancer Prevention
Small study in CANCER indicates finds that 31 of 43 patients with the precancerous laryngeal lesion called leucoplakia demonstrated 50 percent or greater reduction in the lesion size after six months of taking folate supplements.
- Encouraging Results for Folic Acid for Cancer Prevention
Small study in CANCER indicates finds that 31 of 43 patients with the precancerous laryngeal lesion called leucoplakia demonstrated 50 percent or greater reduction in the lesion size after six months of taking folate supplements.
- Encouraging Results for Folic Acid for Cancer Prevention
Small study in CANCER indicates finds that 31 of 43 patients with the precancerous laryngeal lesion called leucoplakia demonstrated 50 percent or greater reduction in the lesion size after six months of taking folate supplements.
- Encouraging Results for Folic Acid for Cancer Prevention
Small study in CANCER indicates finds that 31 of 43 patients with the precancerous laryngeal lesion called leucoplakia demonstrated 50 percent or greater reduction in the lesion size after six months of taking folate supplements.
- Encouraging Results for Folic Acid for Cancer Prevention
Small study in CANCER indicates finds that 31 of 43 patients with the precancerous laryngeal lesion called leucoplakia demonstrated 50 percent or greater reduction in the lesion size after six months of taking folate supplements.
- Encouraging Results for Folic Acid for Cancer Prevention
Small study in CANCER indicates finds that 31 of 43 patients with the precancerous laryngeal lesion called leucoplakia demonstrated 50 percent or greater reduction in the lesion size after six months of taking folate supplements.
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- Study at University of Texas Finds that Next Pharmaceutical’s Nexrutine® Inhibits Prostate Cancer Cell Proliferation
Scientists led by principal investigator, Dr. Pratap Kumar, at the Department of Urology at the University of Texas Health Science Center, San Antonio, Texas have found that a proprietary extract from the bark of the Phellodendron tree prevents the growth of prostate cancer cells in laboratory studies.
- UCLA study shows altering fatty acid levels in diet may reduce prostate cancer growth rate
UCLA researchers, in an animal study published in the Aug. 1 issue of the journal Clinical Cancer Research, have found that altering the fatty acid ratio found in the typical Western diet to include more omega-3 fatty acids and decrease the amount of omega-6 fatty acids may reduce prostate cancer tumor growth rates and PSA levels.
- UCLA study shows altering fatty acid levels in diet may reduce prostate cancer growth rate
UCLA researchers, in an animal study published in the Aug. 1 issue of the journal Clinical Cancer Research, have found that altering the fatty acid ratio found in the typical Western diet to include more omega-3 fatty acids and decrease the amount of omega-6 fatty acids may reduce prostate cancer tumor growth rates and PSA levels.
- UCLA study shows altering fatty acid levels in diet may reduce prostate cancer growth rate
UCLA researchers, in an animal study published in the Aug. 1 issue of the journal Clinical Cancer Research, have found that altering the fatty acid ratio found in the typical Western diet to include more omega-3 fatty acids and decrease the amount of omega-6 fatty acids may reduce prostate cancer tumor growth rates and PSA levels.
- UCLA study shows altering fatty acid levels in diet may reduce prostate cancer growth rate
UCLA researchers, in an animal study published in the Aug. 1 issue of the journal Clinical Cancer Research, have found that altering the fatty acid ratio found in the typical Western diet to include more omega-3 fatty acids and decrease the amount of omega-6 fatty acids may reduce prostate cancer tumor growth rates and PSA levels.
- Vanderbilt-Ingram Cancer Center researchers find ginseng may improve breast cancer outcomes
Study by Vanderbilt-Ingram Cancer Center researchers, published online recently in the American Journal of Epidemiology, indicates that ginseng may improve survival and quality of life after a diagnosis of breast cancer
- Vanderbilt-Ingram Cancer Center researchers find ginseng may improve breast cancer outcomes
Study by Vanderbilt-Ingram Cancer Center researchers, published online recently in the American Journal of Epidemiology, indicates that ginseng may improve survival and quality of life after a diagnosis of breast cancer
- Vanderbilt-Ingram Cancer Center researchers find ginseng may improve breast cancer outcomes
Study by Vanderbilt-Ingram Cancer Center researchers, published online recently in the American Journal of Epidemiology, indicates that ginseng may improve survival and quality of life after a diagnosis of breast cancer
- Vanderbilt-Ingram Cancer Center researchers find ginseng may improve breast cancer outcomes
Study by Vanderbilt-Ingram Cancer Center researchers, published online recently in the American Journal of Epidemiology, indicates that ginseng may improve survival and quality of life after a diagnosis of breast cancer
- Low folate diets found to increase risk of colorectal cancer
new study by scientists at the MUHC, published in the scientific journal Cancer
Research, has revealed that a low level of folate in our diet increases our risk of
developing colorectal cancer.
- Low folate diets found to increase risk of colorectal cancer
new study by scientists at the MUHC, published in the scientific journal Cancer
Research, has revealed that a low level of folate in our diet increases our risk of
developing colorectal cancer.
- Low folate diets found to increase risk of colorectal cancer
new study by scientists at the MUHC, published in the scientific journal Cancer
Research, has revealed that a low level of folate in our diet increases our risk of
developing colorectal cancer.
- Low folate diets found to increase risk of colorectal cancer
new study by scientists at the MUHC, published in the scientific journal Cancer
Research, has revealed that a low level of folate in our diet increases our risk of
developing colorectal cancer.
- Low folate diets found to increase risk of colorectal cancer
new study by scientists at the MUHC, published in the scientific journal Cancer
Research, has revealed that a low level of folate in our diet increases our risk of
developing colorectal cancer.
- Study Indicates GliSODin® Shown to Inhibit Surgery-Related Cellular DNA Damage
P.L. Thomas, in association with Isocell, Paris, France, announced the results of a new study, indicating that GliSODin, supplementation prior to an invasive surgical procedure, was shown to significantly inhibit several measures of cellular damage, including DNA damage and protection of spinal cord tissues, without negative effects or impairing organ function.
- Study Indicates GliSODin® Shown to Inhibit Surgery-Related Cellular DNA Damage
P.L. Thomas, in association with Isocell, Paris, France, announced the results of a new study, indicating that GliSODin, supplementation prior to an invasive surgical procedure, was shown to significantly inhibit several measures of cellular damage, including DNA damage and protection of spinal cord tissues, without negative effects or impairing organ function.
- Study Indicates GliSODin® Shown to Inhibit Surgery-Related Cellular DNA Damage
P.L. Thomas, in association with Isocell, Paris, France, announced the results of a new study, indicating that GliSODin, supplementation prior to an invasive surgical procedure, was shown to significantly inhibit several measures of cellular damage, including DNA damage and protection of spinal cord tissues, without negative effects or impairing organ function.
- Study Indicates GliSODin® Shown to Inhibit Surgery-Related Cellular DNA Damage
P.L. Thomas, in association with Isocell, Paris, France, announced the results of a new study, indicating that GliSODin, supplementation prior to an invasive surgical procedure, was shown to significantly inhibit several measures of cellular damage, including DNA damage and protection of spinal cord tissues, without negative effects or impairing organ function.
- Study Indicates GliSODin® Shown to Inhibit Surgery-Related Cellular DNA Damage
P.L. Thomas, in association with Isocell, Paris, France, announced the results of a new study, indicating that GliSODin, supplementation prior to an invasive surgical procedure, was shown to significantly inhibit several measures of cellular damage, including DNA damage and protection of spinal cord tissues, without negative effects or impairing organ function.
- Harvard Men’s Health Watch: Red wine protects the prostate
Researchers in Seattle collected information about many factors that might influence the risk of prostate cancer in men between ages 40 and 64, including alcohol consumption, determining that men who drink an average of four to seven glasses of red wine per week are only 52% as likely to be diagnosed with prostate cancer as those who do not drink red wine.
- Harvard Men’s Health Watch: Red wine protects the prostate
Researchers in Seattle collected information about many factors that might influence the risk of prostate cancer in men between ages 40 and 64, including alcohol consumption, determining that men who drink an average of four to seven glasses of red wine per week are only 52% as likely to be diagnosed with prostate cancer as those who do not drink red wine.
- Harvard Men’s Health Watch: Red wine protects the prostate
Researchers in Seattle collected information about many factors that might influence the risk of prostate cancer in men between ages 40 and 64, including alcohol consumption, determining that men who drink an average of four to seven glasses of red wine per week are only 52% as likely to be diagnosed with prostate cancer as those who do not drink red wine.
- Harvard Men’s Health Watch: Red wine protects the prostate
Researchers in Seattle collected information about many factors that might influence the risk of prostate cancer in men between ages 40 and 64, including alcohol consumption, determining that men who drink an average of four to seven glasses of red wine per week are only 52% as likely to be diagnosed with prostate cancer as those who do not drink red wine.
- Study Provides Evidence That Maitake D-Fraction® to be Effective Against Bladder Cancer Cells
A study recently published in the Alternative Medicine Review magazine (vol. 12, Number 1, 2007) presented evidence of the superior cancer-inhibiting activity of Grifron®-Pro Maitake D-Fraction® (GD) on human bladder cancer cells over other natural anti-cancer products.
- Study Provides Evidence That Maitake D-Fraction® to be Effective Against Bladder Cancer Cells
A study recently published in the Alternative Medicine Review magazine (vol. 12, Number 1, 2007) presented evidence of the superior cancer-inhibiting activity of Grifron®-Pro Maitake D-Fraction® (GD) on human bladder cancer cells over other natural anti-cancer products.
- Study Provides Evidence That Maitake D-Fraction® to be Effective Against Bladder Cancer Cells
A study recently published in the Alternative Medicine Review magazine (vol. 12, Number 1, 2007) presented evidence of the superior cancer-inhibiting activity of Grifron®-Pro Maitake D-Fraction® (GD) on human bladder cancer cells over other natural anti-cancer products.
- A diet rich in omega-3 fatty acids may lower prostate cancer genetic risk
Researchers observe that, based on amouse model study, a diet rich in omega-3 polyunsaturated fatty acids found in certain fish or fish oil, nuts, seeds, and vegetable oils may help lower prostate cancer risk in individuals with a genetic predisposition to cancer.
- A diet rich in omega-3 fatty acids may lower prostate cancer genetic risk
Researchers observe that, based on amouse model study, a diet rich in omega-3 polyunsaturated fatty acids found in certain fish or fish oil, nuts, seeds, and vegetable oils may help lower prostate cancer risk in individuals with a genetic predisposition to cancer.
- A diet rich in omega-3 fatty acids may lower prostate cancer genetic risk
Researchers observe that, based on amouse model study, a diet rich in omega-3 polyunsaturated fatty acids found in certain fish or fish oil, nuts, seeds, and vegetable oils may help lower prostate cancer risk in individuals with a genetic predisposition to cancer.
- A diet rich in omega-3 fatty acids may lower prostate cancer genetic risk
Researchers observe that, based on amouse model study, a diet rich in omega-3 polyunsaturated fatty acids found in certain fish or fish oil, nuts, seeds, and vegetable oils may help lower prostate cancer risk in individuals with a genetic predisposition to cancer.
- Green tea may halve risk of colon cancer
A study from China, published in Cancer Epidemiology, Biomarkers and Prevention, has reported beneficial associations between regular consumption of green tea and colorectal cancer risk.
- Green tea may halve risk of colon cancer
A study from China, published in Cancer Epidemiology, Biomarkers and Prevention, has reported beneficial associations between regular consumption of green tea and colorectal cancer risk.
- Green tea may halve risk of colon cancer
A study from China, published in Cancer Epidemiology, Biomarkers and Prevention, has reported beneficial associations between regular consumption of green tea and colorectal cancer risk.
- Cargill announces positive results of clinical study using Cosucra's prebiotic inulin
A double-blind, randomized, placebo-controlled study, published in the journal Nutrition Research, has found that after four weeks of consuming 2.5 grams of inulin twice daily, there was a 10-fold increase in counts of beneficial Bifidobacteria among healthy volunteers. According to a releasze issued by Cargill, which distributes the prebiotic inulin used in the study, those consuming inulin also experienced a noted decrease in activity of beta-glucuronidase, an enzyme that may play a role in increasing the amount of carcinogens in the colon.
- Cargill announces positive results of clinical study using Cosucra's prebiotic inulin
A double-blind, randomized, placebo-controlled study, published in the journal Nutrition Research, has found that after four weeks of consuming 2.5 grams of inulin twice daily, there was a 10-fold increase in counts of beneficial Bifidobacteria among healthy volunteers. According to a releasze issued by Cargill, which distributes the prebiotic inulin used in the study, those consuming inulin also experienced a noted decrease in activity of beta-glucuronidase, an enzyme that may play a role in increasing the amount of carcinogens in the colon.
- Cargill announces positive results of clinical study using Cosucra's prebiotic inulin
A double-blind, randomized, placebo-controlled study, published in the journal Nutrition Research, has found that after four weeks of consuming 2.5 grams of inulin twice daily, there was a 10-fold increase in counts of beneficial Bifidobacteria among healthy volunteers. According to a releasze issued by Cargill, which distributes the prebiotic inulin used in the study, those consuming inulin also experienced a noted decrease in activity of beta-glucuronidase, an enzyme that may play a role in increasing the amount of carcinogens in the colon.
- New Cell Research Confirms Wild Blueberry Antioxidant Power
New research published in the current issue of the Journal of Agricultural and Food Chemistry (55 (22), 8896-8907, 2007) shows that Wild Blueberries have the highest cellular antioxidant activity of selected fruits tested.
- New Cell Research Confirms Wild Blueberry Antioxidant Power
New research published in the current issue of the Journal of Agricultural and Food Chemistry (55 (22), 8896-8907, 2007) shows that Wild Blueberries have the highest cellular antioxidant activity of selected fruits tested.
- New Cell Research Confirms Wild Blueberry Antioxidant Power
New research published in the current issue of the Journal of Agricultural and Food Chemistry (55 (22), 8896-8907, 2007) shows that Wild Blueberries have the highest cellular antioxidant activity of selected fruits tested.
- New Cell Research Confirms Wild Blueberry Antioxidant Power
New research published in the current issue of the Journal of Agricultural and Food Chemistry (55 (22), 8896-8907, 2007) shows that Wild Blueberries have the highest cellular antioxidant activity of selected fruits tested.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Another Reason to Choose Healthy Lifestyle Habits
- Another Reason to Choose Healthy Lifestyle Habits
|
Toronto, Canada (15 August 2006) - glisodin.org, an international research community dedicated to the Glisodin SOD/gliadin complex, announces the inclusion of a key study on Glisodin and immune compromised individuals at the AIDS 2006 - XVI International AIDS Conference, August 13-18 2006, held in Toronto. In this study, Glisodin was shown to restore the circulating antioxidant capacities, including Superoxide Dismustase (SOD), in the Glisodin group as compared to no change in the control and placebo group. SOD is an endogenous antioxidant produced by the body at the cellular level, providing the first line of defense against oxidative stress.
"The effects of an orally effective SOD (Glisodin) on AIDS West African patients in a randomized double-blinded clinical study," was conducted by French and American Researchers with HIV patients in the Ivory Coast. http://www.iasociety.org/abstract/show.asp?abstract_id=2180443.
Acquired immunodeficiency syndrome (AIDS) is associated with oxidative stress that is responsible for the development of pro-inflammatory disorders and organ failures. In addition, usual anti-retroviral therapies induce important oxidative disorders in promoting mitochondrial swelling, and thus contribute to the development of oxidative disorders in HIV/AIDS infected patients.
The cumulative pro-oxidant effects of the infectious process itself and the potential toxicity of the anti-retroviral therapies could be the origin of most of the inflammatory and toxicological disorders observed in these patients. The objectives of the study were to assess the effects of orally effective SOD/gliadin (Glisodin) on AIDS patients.
In the study, thirty-five AIDS patients were blindly divided into three groups: 1. Placebo (n=12); 2. Non-protected SOD (1000 IU/day, n = 12) as a control; and 3. SOD/Gliadin (Glisodin) product (1000 IU /per day, n = 11). The study products were to be taken once daily, orally for 21 days. Prior to the study, it was first documented that the circulating antioxidant status and the endogenous SOD levels of the study population (n=35) was significantly decreased (p < 0.01) compared to non-infected healthy West African donors.
A statistically significant restoration of the circulating antioxidant capacities was observed in AIDS patients (n = 11) taking the SOD/Gliadin (Glisodin) product: SOD1 activity (p<0.01), Gpx activity (p<0.05), total antioxidant status (p<0.001) and significantly reduced b2-microglobulin plasma concentration (p < 0.01) , during the same period no significant effects were observed for the Non-protected SOD and Placebo groups. This demonstrates that only the SOD/Gliadin preparation was able to efficiently support the antioxidant defenses in AIDS patients.
The authors concluded, "The statistically significant antioxidant restoration and decreased b2-microglobulin concentration in Glisodin-supplemented AIDS patients suggests a beneficial effect of the Glisodin product in HIV/AIDS patients. These results suggest that these patients will be prepared for a better compliance and a better efficacy to the anti-retroviral therapy."
www.Glisodin.org provides research links and studies establishing proof of concept in vitro and in vivo, and efficacy in animal and human models. Human studies include protection of mitochondrial DNA, inhibition of isoprostanes, protection against UV radiation and sun allergy, and other therapeutic benefits of Glisodin supplementation.
International contact: Francois Vix [33] 1 53 98 85 00
U.S. Contact: Eric Anderson
480-227-9383
eric@glisodin.org
# # #
glisodin.org is a research community dedicated to the understanding and advancement of glisodin SOD/gliadin complex. www.glisodin.org |